Obesity and Nonalcoholic Fatty Liver Disease

Amanda Chaney

doi:10.1016/j.cnur.2021.07.009

Obesity and Nonalcoholic Fatty Liver Disease

Nurs Clin North Am. 2021 Dec;56(4):543-552. doi: 10.1016/j.cnur.2021.07.009.

Author

Amanda Chaney¹

Affiliation

¹ Department of Transplant, Mayo Clinic College of Medicine, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Electronic address: CHANEY.AMANDA@MAYO.EDU.

PMID: 34749893
DOI: 10.1016/j.cnur.2021.07.009

Abstract

Obesity and nonalcoholic fatty liver disease (NAFLD) have a significant global impact, and their complications are quickly becoming a reason for primary care visits and hospitalizations. This article provides an overview of NAFLD and obesity, pathogenesis of NAFLD and nonalcoholic steatohepatitis, clinical presentation and diagnostic criteria, and a review of practice guidelines. The current mainstay of treatment for NAFLD are lifestyle modifications and include a plan to eat, move, and change behavior. The future holds potential for new drug therapies in treating NAFLD. More research is needed to move these treatments forward.

Keywords: Fatty liver disease; NAFLD; NASH; Obesity.

Publication types

Review

MeSH terms

Cardiovascular Diseases / etiology*
Diet Therapy*
Exercise*
Humans
Non-alcoholic Fatty Liver Disease / complications*
Non-alcoholic Fatty Liver Disease / drug therapy
Non-alcoholic Fatty Liver Disease / physiopathology*
Obesity* / physiopathology
Obesity* / therapy
Sedentary Behavior